financetom
Business
financetom
/
Business
/
Correction: Update: Market Chatter: US Exploring Equity Stakes in Chipmakers Receiving CHIPS Act Funds
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Correction: Update: Market Chatter: US Exploring Equity Stakes in Chipmakers Receiving CHIPS Act Funds
Aug 21, 2025 7:38 AM

10:18 AM EDT, 08/21/2025 (MT Newswires) -- (Corrects story to denote President Donald Trump is the current president. Updates with Taiwan Semiconductor's comment in the fifth paragraph.)

US Commerce Secretary Howard Lutnick is exploring the possibility of the federal government taking equity stakes in semiconductor companies that receive CHIPS Act funding to build factories in the US, Reuters reported Wednesday, citing sources.

The idea expands on an existing plan for the US to receive an equity stake in Intel ( INTC ) in exchange for federal grants, the report said.

Lutnick is looking to apply this approach to other major recipients, including Micron (MU), Taiwan Semiconductor Manufacturing ( TSM ) , and Samsung, Reuters reported. Most CHIPS Act funds have yet to be distributed, the report added.

Treasury Secretary Scott Bessent is also involved in the discussions, sources told Reuters. However, they said Lutnick is the main advocate for the equity-based funding model and that President Trump supports the idea.

Taiwan Semiconductor declined to comment, while Micron and Samsung did not immediately respond to requests for comment.

The Commerce Department oversees the $52.7 billion CHIPS and Science Act, which provides funding for semiconductor research and domestic factory construction.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 23.05, Change: -0.49, Percent Change: -2.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Meta says gen AI had muted impact on global elections this year
Meta says gen AI had muted impact on global elections this year
Dec 3, 2024
Dec 3 (Reuters) - Despite widespread concern that generative AI could interfere with major elections around the globe this year, the technology had limited impact across Meta Platforms' ( META ) apps, the tech company said on Tuesday. Coordinated networks of accounts seeking to spread propaganda or false content largely failed to build a significant audience on Facebook and Instagram...
Prudential Financial's asset management arm purchases $500 mln of Affirm loans
Prudential Financial's asset management arm purchases $500 mln of Affirm loans
Dec 3, 2024
Dec 3 (Reuters) - Prudential Financial's ( PRU ) fixed income asset management arm has bought $500 million of loans from buy now, pay later firm Affirm Holdings ( AFRM ), the companies said on Tuesday. ...
Constellation Brands to Divest Svedka Brand to Sazerac
Constellation Brands to Divest Svedka Brand to Sazerac
Dec 3, 2024
07:59 AM EST, 12/03/2024 (MT Newswires) -- Constellation Brands ( STZ ) said Tuesday that it has signed a deal with distilled spirits company Sazerac to divest Constellation's Svedka brand. Financial terms of the deal were not disclosed. The company said it plans to complete the deal in the coming months. ...
Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals
Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals
Dec 3, 2024
07:59 AM EST, 12/03/2024 (MT Newswires) -- Roivant Sciences ( ROIV ) said Tuesday its Kinevant Sciences unit's phase 2 Resolve-Lung trial for namilumab in chronic active pulmonary sarcoidosis failed to meet its primary and secondary endpoints. Namilumab failed to meet the primary endpoint, showing no treatment benefit over placebo in reducing Rescue Events during the double-blind period. Secondary endpoints,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved